-
1
-
-
0036528298
-
Focus on colon cancer
-
12086859 10.1016/S1535-6108(02)00053-3 1:CAS:528:DC%2BD38XjsFGltrk%3D
-
Markowitz SD, Dawson DM, Willis J, et al. Focus on colon cancer. Cancer Cell. 2002;1:233-236.
-
(2002)
Cancer Cell
, vol.1
, pp. 233-236
-
-
Markowitz, S.D.1
Dawson, D.M.2
Willis, J.3
-
2
-
-
0036407230
-
Genetic and epigenetic alterations in colon cancer
-
12142355 10.1146/annurev.genom.3.022502.103043 1:CAS:528: DC%2BD3sXktlCktw%3D%3D
-
Grady WM, Markowitz SD. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet. 2002;3:101-128.
-
(2002)
Annu Rev Genomics Hum Genet
, vol.3
, pp. 101-128
-
-
Grady, W.M.1
Markowitz, S.D.2
-
3
-
-
72449176846
-
Molecular origins of cancer: Molecular basis of colorectal cancer
-
20018966 10.1056/NEJMra0804588 1:CAS:528:DC%2BD1MXhsFKisr7L
-
Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449-2460.
-
(2009)
N Engl J Med
, vol.361
, pp. 2449-2460
-
-
Markowitz, S.D.1
Bertagnolli, M.M.2
-
4
-
-
13544268334
-
15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer
-
15542609 10.1074/jbc.M411221200 1:CAS:528:DC%2BD2MXovVCrug%3D%3D
-
Backlund MG, Mann JR, Holla VR, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem. 2005;280:3217-3223.
-
(2005)
J Biol Chem
, vol.280
, pp. 3217-3223
-
-
Backlund, M.G.1
Mann, J.R.2
Holla, V.R.3
-
5
-
-
33747081906
-
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis
-
16880406 10.1073/pnas.0603235103 1:CAS:528:DC%2BD28Xotlyju7Y%3D
-
Myung SJ, Rerko RM, Yan M, et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA. 2006;103:12098-12102.
-
(2006)
Proc Natl Acad Sci USA
, vol.103
, pp. 12098-12102
-
-
Myung, S.J.1
Rerko, R.M.2
Yan, M.3
-
6
-
-
10644274362
-
15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers
-
15574495 10.1073/pnas.0406142101 1:CAS:528:DC%2BD2MXhslOjtQ%3D%3D
-
Yan M, Rerko RM, Platzer P, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA. 2004;101:17468-17473.
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, pp. 17468-17473
-
-
Yan, M.1
Rerko, R.M.2
Platzer, P.3
-
7
-
-
67249157211
-
15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors
-
19470469 10.1073/pnas.0902367106 1:CAS:528:DC%2BD1MXot1CgurY%3D
-
Yan M, Myung SJ, Fink SP, et al. 15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci USA. 2009;106:9409-9413.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 9409-9413
-
-
Yan, M.1
Myung, S.J.2
Fink, S.P.3
-
8
-
-
33748180713
-
Celecoxib for the prevention of colorectal adenomatous polyps
-
16943401 10.1056/NEJMoa061652 1:CAS:528:DC%2BD28XovFehurc%3D
-
Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885-895.
-
(2006)
N Engl J Med
, vol.355
, pp. 885-895
-
-
Arber, N.1
Eagle, C.J.2
Spicak, J.3
-
9
-
-
0037421985
-
A randomized trial of aspirin to prevent colorectal adenomas
-
12621133 10.1056/NEJMoa021735 1:CAS:528:DC%2BD3sXhvVOitrw%3D
-
Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891-899.
-
(2003)
N Engl J Med
, vol.348
, pp. 891-899
-
-
Baron, J.A.1
Cole, B.F.2
Sandler, R.S.3
-
10
-
-
33748196958
-
Celecoxib for the prevention of sporadic colorectal adenomas
-
16943400 10.1056/NEJMoa061355 1:CAS:528:DC%2BD28XovFaju7Y%3D
-
Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355:873-884.
-
(2006)
N Engl J Med
, vol.355
, pp. 873-884
-
-
Bertagnolli, M.M.1
Eagle, C.J.2
Zauber, A.G.3
-
11
-
-
0037421984
-
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer
-
12621132 10.1056/NEJMoa021633 1:CAS:528:DC%2BD3sXhvVOisbw%3D
-
Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883-890.
-
(2003)
N Engl J Med
, vol.348
, pp. 883-890
-
-
Sandler, R.S.1
Halabi, S.2
Baron, J.A.3
-
12
-
-
84860250352
-
Use of aspirin postdiagnosis improves survival for colon cancer patients
-
22454078 10.1038/bjc.2012.101 1:CAS:528:DC%2BC38Xmt1Ghu7c%3D
-
Bastiaannet E, Sampieri K, Dekkers OM, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer. 2012;106:1564-1570.
-
(2012)
Br J Cancer
, vol.106
, pp. 1564-1570
-
-
Bastiaannet, E.1
Sampieri, K.2
Dekkers, O.M.3
-
13
-
-
83955161674
-
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: An analysis from the CAPP2 randomised controlled trial
-
22036019 10.1016/S0140-6736(11)61049-0
-
Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378:2081-2087.
-
(2011)
Lancet
, vol.378
, pp. 2081-2087
-
-
Burn, J.1
Gerdes, A.M.2
Macrae, F.3
-
14
-
-
84855556537
-
Aspirin in the chemoprevention of colorectal neoplasia: An overview
-
10.1158/1940-6207.CAPR-11-0391 1:CAS:528:DC%2BC38XjvValtb0%3D
-
Chan AT, Arber N, Burn J, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila). 2012;5:164-178.
-
(2012)
Cancer Prev Res (Phila)
, vol.5
, pp. 164-178
-
-
Chan, A.T.1
Arber, N.2
Burn, J.3
-
15
-
-
64149097786
-
The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments
-
19246619 10.1373/clinchem.2008.112797 1:CAS:528:DC%2BD1MXktVWqs7g%3D
-
Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611-622.
-
(2009)
Clin Chem
, vol.55
, pp. 611-622
-
-
Bustin, S.A.1
Benes, V.2
Garson, J.A.3
-
16
-
-
60549115231
-
Gastrointestinal differentiation marker Cytokeratin 20 is regulated by homeobox gene CDX1
-
19188603 10.1073/pnas.0812904106
-
Chan CW, Wong NA, Liu Y, et al. Gastrointestinal differentiation marker Cytokeratin 20 is regulated by homeobox gene CDX1. Proc Natl Acad Sci USA. 2009;106:1936-1941.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 1936-1941
-
-
Chan, C.W.1
Wong, N.A.2
Liu, Y.3
-
17
-
-
0025354008
-
Identification of protein IT of the intestinal cytoskeleton as a novel type i cytokeratin with unusual properties and expression patterns
-
1696264 10.1083/jcb.111.2.567 1:CAS:528:DyaK3cXkvFKqurk%3D
-
Moll R, Schiller DL, Franke WW. Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns. J Cell Biol. 1990;111:567-580.
-
(1990)
J Cell Biol
, vol.111
, pp. 567-580
-
-
Moll, R.1
Schiller, D.L.2
Franke, W.W.3
-
18
-
-
0032903863
-
Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months
-
10334197 10.1093/carcin/20.5.805 1:CAS:528:DyaK1MXjtVantbw%3D
-
Williamson SL, Kartheuser A, Coaker J, et al. Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months. Carcinogenesis. 1999;20:805-810.
-
(1999)
Carcinogenesis
, vol.20
, pp. 805-810
-
-
Williamson, S.L.1
Kartheuser, A.2
Coaker, J.3
-
19
-
-
34249711291
-
Aspirin and colon cancer-targeting prevention?
-
17522404 10.1056/NEJMe078044 1:CAS:528:DC%2BD2sXlvVCntbc%3D
-
Markowitz SD. Aspirin and colon cancer-targeting prevention? N Engl J Med. 2007;356:2195-2198.
-
(2007)
N Engl J Med
, vol.356
, pp. 2195-2198
-
-
Markowitz, S.D.1
-
20
-
-
33845288081
-
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas
-
17087947 10.1053/j.gastro.2006.08.079 1:CAS:528:DC%2BD2sXhtFyltL8%3D
-
Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology. 2006;131:1674-1682.
-
(2006)
Gastroenterology
, vol.131
, pp. 1674-1682
-
-
Baron, J.A.1
Sandler, R.S.2
Bresalier, R.S.3
-
21
-
-
19744380776
-
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
-
15713943 10.1056/NEJMoa050493 1:CAS:528:DC%2BD2MXit1Kqu7o%3D
-
Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-1102.
-
(2005)
N Engl J Med
, vol.352
, pp. 1092-1102
-
-
Bresalier, R.S.1
Sandler, R.S.2
Quan, H.3
-
22
-
-
20144365496
-
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention
-
15713944 10.1056/NEJMoa050405 1:CAS:528:DC%2BD2MXit1Kqur4%3D
-
Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-1080.
-
(2005)
N Engl J Med
, vol.352
, pp. 1071-1080
-
-
Solomon, S.D.1
McMurray, J.J.2
Pfeffer, M.A.3
|